pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
Company profile
Ticker
PLRX
Exchange
Website
CEO
Bernard Coulie
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
474272481
PLRX stock data
Latest filings (excl ownership)
8-K
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan
12 Mar 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC
27 Feb 24
8-K
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data
5 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC
9 Nov 23
8-K
Entry into a Material Definitive Agreement
3 Oct 23
8-K
Other Events
26 Sep 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
Latest ownership filings
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G
First Light Asset Management, LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Third Rock Ventures III, L.P.
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
Laurion Capital Management LP
8 Feb 24
SC 13G
BlackRock Inc.
25 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.68 mm | 57.68 mm | 57.68 mm | 57.68 mm | 57.68 mm | 57.68 mm |
Cash burn (monthly) | (no burn) | (no burn) | 15.90 mm | 14.54 mm | 12.07 mm | 10.21 mm |
Cash used (since last report) | n/a | n/a | 95.00 mm | 86.92 mm | 72.17 mm | 61.01 mm |
Cash remaining | n/a | n/a | -37.32 mm | -29.24 mm | -14.49 mm | -3.33 mm |
Runway (months of cash) | n/a | n/a | -2.3 | -2.0 | -1.2 | -0.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 140 |
Opened positions | 24 |
Closed positions | 31 |
Increased positions | 51 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 1.04 tn |
Total shares | 64.44 mm |
Total puts | 96.00 k |
Total calls | 262.80 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Deep Track Capital | 5.50 mm | $95.37 bn |
BLK Blackrock | 4.32 mm | $74.95 bn |
FMR | 4.14 mm | $71.81 bn |
T. Rowe Price | 3.35 mm | $58.26 bn |
Laurion Capital Management | 3.19 mm | $55.25 bn |
CHI Advisors | 3.01 mm | $52.27 bn |
Vanguard | 2.95 mm | $51.07 bn |
First Light Asset Management | 2.93 mm | $50.86 bn |
Redmile | 2.68 mm | $46.44 bn |
Novartis Institutes for BioMedical Research | 2.15 mm | $40.98 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jan 24 | Keith Lamont Cummings | Common Stock | Grant | Acquire A | No | No | 0 | 55,250 | 0.00 | 249,855 |
23 Jan 24 | Keith Lamont Cummings | Stock Option Common Stock | Grant | Acquire A | No | No | 17.44 | 110,500 | 1.93 mm | 110,500 |
23 Jan 24 | Lily Cheung | Common Stock | Grant | Acquire A | No | No | 0 | 26,000 | 0.00 | 26,795 |
23 Jan 24 | Lily Cheung | Stock Option Common Stock | Grant | Acquire A | No | No | 17.44 | 52,000 | 906.88 k | 52,000 |
23 Jan 24 | Bernard Coulie | Common Stock | Grant | Acquire A | No | No | 0 | 128,150 | 0.00 | 444,532 |
23 Jan 24 | Bernard Coulie | Stock Option Common Stock | Grant | Acquire A | No | No | 17.44 | 256,300 | 4.47 mm | 256,300 |
23 Jan 24 | Lefebvre Eric | Common Stock | Grant | Acquire A | No | No | 0 | 42,900 | 0.00 | 199,820 |
23 Jan 24 | Lefebvre Eric | Stock Option Common Stock | Grant | Acquire A | No | No | 17.44 | 85,800 | 1.50 mm | 85,800 |
23 Jan 24 | Hull Hans | Common Stock | Grant | Acquire A | No | No | 0 | 31,500 | 0.00 | 216,569 |
23 Jan 24 | Hull Hans | Stock Option Common Stock | Grant | Acquire A | No | No | 17.44 | 63,000 | 1.10 mm | 63,000 |
News
Needham Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target
12 Mar 24
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
12 Mar 24
RBC Capital Maintains Outperform on Pliant Therapeutics, Raises Price Target to $54
5 Mar 24
HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $48 Price Target
28 Feb 24
RBC Capital Maintains Outperform on Pliant Therapeutics, Lowers Price Target to $50
28 Feb 24
Press releases
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
27 Mar 24
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
12 Mar 24
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
12 Mar 24
Pliant Therapeutics to Participate in Upcoming Investor Conferences
26 Feb 24
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
4 Feb 24